Clinical Trials
40 trialsMC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer
Mayo Clinic
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery
Radiation Therapy Oncology Group
STARTRK-2
Hoffmann-La Roche
Sensor-Assisted Prevention of Dehydration in Head and Neck Cancer Patients
M.D. Anderson Cancer Center
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
Avacta Life Sciences Ltd
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers
National Cancer Institute (NCI)
YATAGARASU
Janssen Pharmaceutical K.K.
Amivantamab in Adenoid Cystic Carcinoma
University of Cincinnati
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
NRG Oncology
NAVIGATE
Bayer
Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
Dana-Farber Cancer Institute
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
Mayo Clinic
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Jazz Pharmaceuticals
Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)
National Cancer Center Hospital East
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Peking Union Medical College
STARTRK-NG
Hoffmann-La Roche
Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers
M.D. Anderson Cancer Center
iPRIME
University of Chicago
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
National Cancer Institute (NCI)
APG-115 in Salivary Gland Cancer Trial
University of Michigan Rogel Cancer Center
ACUPUNCTURE
Wake Forest University Health Sciences
VISTA
Baylor College of Medicine
Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers
Brigham and Women's Hospital
A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes
University Health Network, Toronto
Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma
Big Ten Cancer Research Consortium
Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer
Memorial Sloan Kettering Cancer Center
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VM Oncology, LLC
DETERMINE
Cancer Research UK
Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
Memorial Sloan Kettering Cancer Center
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
LigaChem Biosciences, Inc.
KEYNOTE 158
Merck Sharp & Dohme LLC
PSGT
Abramson Cancer Center at Penn Medicine
Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer
M.D. Anderson Cancer Center
EARN
Washington University School of Medicine
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer
QBiotics Group Limited
I-MAC
Dana-Farber Cancer Institute
TROP2
National University Hospital, Singapore